PMC:6909918 / 31130-31847 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/6909918","sourcedb":"PMC","sourceid":"6909918","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6909918","text":"Supplementary Data\nSupplementary Figure 1 Indirect comparisons for PFS among Fruq (fruquintinib), Reg (regorafenib), TAS (TAS-102), and PLA (placebo) among trials of FRESCO, TERRA, and CONCUR.\nSupplementary Figure 2 Indirect comparisons for OS among Fruq (fruquintinib), Reg (regorafenib), TAS (TAS-102), and PLA (placebo) among trials of FRESCO, TERRA, and CONCUR.\nSupplementary Figure 3 Indirect comparisons for ORR among Fruq (fruquintinib), Reg (regorafenib), TAS (TAS-102), and PLA (placebo) among trials of FRESCO, TERRA, and CONCUR.\nSupplementary Figure 4 Indirect comparisons for DCR among Fruq (fruquintinib), Reg (regorafenib), TAS (TAS-102), and PLA (placebo) among trials of FRESCO, TERRA, and CONCUR.","divisions":[{"label":"title","span":{"begin":0,"end":18}},{"label":"label","span":{"begin":19,"end":41}},{"label":"caption","span":{"begin":43,"end":193}},{"label":"p","span":{"begin":43,"end":193}},{"label":"label","span":{"begin":194,"end":216}},{"label":"caption","span":{"begin":218,"end":367}},{"label":"p","span":{"begin":218,"end":367}},{"label":"label","span":{"begin":368,"end":390}},{"label":"caption","span":{"begin":392,"end":542}},{"label":"p","span":{"begin":392,"end":542}},{"label":"label","span":{"begin":543,"end":565}}],"tracks":[]}